It demonstrated the disproportionate disease burden of T2DM and aggressive disease progression to the need for insulin therapy for hyperglycaemia management amongst younger children with T2DM who are morbidly obese and at‐risk minorities. The gene discussed is INS; the disease is Hyperglycemia.